

Carlos Camps

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2705277/publications.pdf>

Version: 2024-02-01

169
papers

11,861
citations

57758

44
h-index

27406

106
g-index

185
all docs

185
docs citations

185
times ranked

12531
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	27.0	2,213
2	A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1994, 330, 153-158.	27.0	1,204
3	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2286-91.	7.0	532
4	The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 209-217.	1.1	502
5	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	1.6	445
6	Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. <i>Lung Cancer</i> , 1999, 26, 7-14.	2.0	367
7	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	1.6	351
8	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 1318-1325.	7.0	345
9	Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. <i>Lung Cancer</i> , 2006, 51, 143-158.	2.0	310
10	The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 824-833.	1.1	276
11	Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 1194-1203.	1.2	270
12	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. <i>British Journal of Cancer</i> , 2011, 104, 1168-1177.	6.4	244
13	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2005, 16, 1081-1086.	1.2	217
14	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	1.6	177
15	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	10.7	172
16	Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2006, 17, 668-675.	1.2	159
17	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21). <i>Journal of Clinical Oncology</i> , 2003, 21, 833-842.	1.2	145
18	Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 209-215.	3.1	135

#	ARTICLE	IF	CITATIONS
19	Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. <i>Lung Cancer</i> , 2005, 49, 1-12.	2.0	133
20	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1385-1393.	6.3	127
21	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
22	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006, 17, 467-472.	1.2	117
23	14-3-3 β Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non-Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9105-9112.	1.6	114
24	Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1377-1382.	1.6	110
25	Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 135.	4.4	86
26	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1164-1176.	5.6	77
27	Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 286-290.	1.1	75
28	Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 651-657.	2.4	75
29	Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 12904-12916.	1.8	73
30	Circulating tumor cells versus circulating tumor DNA in lung cancer— which one will win?. <i>Translational Lung Cancer Research</i> , 2016, 5, 466-482.	2.8	72
31	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010, 46, 735-743.	2.8	71
32	Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004, 15, 79-87.	1.2	69
33	Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. <i>Cell Death and Disease</i> , 2019, 10, 660.	6.3	68
34	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
35	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. <i>PLoS ONE</i> , 2020, 15, e0228909.	2.5	66
36	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017, 25, 3295-3304.	2.2	64

#	ARTICLE	IF	CITATIONS
37	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1464-1470.	6.4	62
38	The role of the clinical research coordinator “ data manager ” in oncology clinical trials. <i>BMC Medical Research Methodology</i> , 2004, 4, 6.	3.1	54
39	Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin-Treated Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2003, 4, 237-241.	2.6	48
40	Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. <i>Lung Cancer</i> , 2011, 74, 326-331.	2.0	48
41	MicroRNAs: Promising New Antiangiogenic Targets in Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	48
42	Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 42, 345-354.	2.0	47
43	Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2005, 50, 339-346.	2.0	47
44	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1260-1266.	1.1	46
45	Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1071-1077.	1.6	45
46	The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2011, 72, 365-369.	2.0	43
47	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). <i>Translational Lung Cancer Research</i> , 2019, 8, 461-475.	2.8	38
48	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. <i>Oncotarget</i> , 2018, 9, 4395-4410.	1.8	37
49	Targeted therapy in combination with gemcitabine in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 19-25.	2.2	34
50	Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. <i>Journal of Oral Pathology and Medicine</i> , 2014, 43, 371-377.	2.7	34
51	Influence of genetic markers on survival in non-small cell lung cancer. <i>Drugs of Today</i> , 2003, 39, 775.	2.4	33
52	Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. <i>Oncotarget</i> , 2016, 7, 52849-52861.	1.8	33
53	3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. <i>Materials Science and Engineering C</i> , 2021, 122, 111914.	7.3	32
54	Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, 175-183.	2.6	31

#	ARTICLE	IF	CITATIONS
55	Importance of Quality of Life in Patients with Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 83-90.	2.6	31
56	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
57	Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 488-494.	1.8	30
58	Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. <i>Lung Cancer</i> , 2000, 27, 47-53.	2.0	29
59	Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. <i>Lung Cancer</i> , 2006, 52, 343-347.	2.0	29
60	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012, 76, 354-361.	2.0	29
61	miRNA detection methods and clinical implications in lung cancer. <i>Future Oncology</i> , 2014, 10, 2279-2292.	2.4	29
62	Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. <i>European Journal of Cancer</i> , 2002, 38, 1204-1211.	2.8	28
63	Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. <i>Supportive Care in Cancer</i> , 2006, 14, 1173-1183.	2.2	28
64	Gene Expression and Polymorphisms of DNA Repair Enzymes: Cancer Susceptibility and Response to Chemotherapy. <i>Clinical Lung Cancer</i> , 2007, 8, 369-375.	2.6	28
65	Management of malignant insulinoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 725-731.	2.4	28
66	MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. <i>Oncotarget</i> , 2017, 8, 56143-56157.	1.8	28
67	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	1.2	27
68	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. <i>Oral Diseases</i> , 2015, 21, 899-904.	3.0	27
69	EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 52-63.	4.4	26
70	Pharmacogenomics and gemcitabine. <i>Annals of Oncology</i> , 2006, 17, v13-v16.	1.2	25
71	Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in Stage IIIA non-small cell lung cancer. <i>Lung Cancer</i> , 1995, 12, S59-S70.	2.0	24
72	Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. <i>BMC Cancer</i> , 2010, 10, 26.	2.6	24

#	ARTICLE	IF	CITATIONS
73	A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 612-620.	1.5	24
74	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	2.0	24
75	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, 597-601.	1.2	23
76	Cytophagic histiocytic panniculitis. <i>Journal of the American Academy of Dermatology</i> , 1989, 20, 875-878.	1.2	22
77	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 883-890.	2.3	22
78	Update on biomarkers for the detection of lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2012, 3, 21.	2.7	22
79	Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients with Cisplatin/Gemcitabine-Treated Stage IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 5, 360-365.	2.6	21
80	A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 575-582.	3.1	21
81	Pain in clinical oncology: Patient satisfaction with management of cancer pain. <i>European Journal of Pain</i> , 2012, 16, 381-389.	2.8	20
82	Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 20.	2.4	20
83	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. <i>Cancers</i> , 2022, 14, 307.	3.7	20
84	Update on systemic treatment in early triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098674.	3.2	19
85	Lung cancer and treatment in elderly patients: The Achilles Study. <i>Lung Cancer</i> , 2009, 66, 103-106.	2.0	18
86	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 977-984.	2.4	18
87	Treatment of Advanced Colorectal Cancer with Recombinant Interferon Alpha and Fluorouracil: Activity in Liver Metastasis. <i>Cancer Investigation</i> , 1992, 10, 259-264.	1.3	17
88	Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2011, 12, 224-230.	2.6	17
89	Breakthrough cancer pain: review and calls to action to improve its management. <i>Clinical and Translational Oncology</i> , 2020, 22, 1216-1226.	2.4	17
90	Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 1997, 17, 261-269.	2.0	16

#	ARTICLE	IF	CITATIONS
91	5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy. <i>Annals of Oncology</i> , 1993, 4, 753-757.	1.2	15
92	Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2011, 12, 320-327.	2.6	15
93	Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws. <i>Oral Diseases</i> , 2014, 20, 446-452.	3.0	15
94	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1067-1075.	1.1	15
95	dPCR application in liquid biopsies: divide and conquer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 3-15.	3.1	15
96	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , 2018, 9, 20282-20293.	1.8	15
97	Oncologists' perceptions of cancer pain management in Spain: The real and the ideal. <i>European Journal of Pain</i> , 2007, 11, 352-359.	2.8	14
98	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1074-1083.	2.8	14
99	Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 83-87.	2.0	13
100	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.	2.0	13
101	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. <i>Journal of Thoracic Disease</i> , 2017, 9, S1332-S1345.	1.4	13
102	Oncologists' knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. <i>Clinical and Translational Oncology</i> , 2018, 20, 613-618.	2.4	13
103	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. <i>Journal of Thoracic Disease</i> , 2020, 12, 2771-2780.	1.4	13
104	Exosomal microRNAs in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	1.0	13
105	Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. <i>Clinical Lung Cancer</i> , 2000, 1, 287-293.	2.6	12
106	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2950.	3.7	12
107	Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2006, 26, 4905-9.	1.1	12
108	Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. <i>Cancer</i> , 2002, 95, 2408-2413.	4.1	11

#	ARTICLE	IF	CITATIONS
109	Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 63-67.	2.0	11
110	SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. <i>Supportive Care in Cancer</i> , 2016, 24, 499-507.	2.2	11
111	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <i>Oncolmunology</i> , 2017, 6, e1260214.	4.6	11
112	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1683-1693.	1.8	10
113	The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. <i>Clinical and Translational Oncology</i> , 2011, 13, 396-400.	2.4	10
114	Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). <i>Clinical and Translational Oncology</i> , 2019, 21, 380-390.	2.4	10
115	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.	2.0	10
116	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 21-31.	1.7	9
117	Epidermoid carcinoma of the colon. <i>Diseases of the Colon and Rectum</i> , 1986, 29, 665-667.	1.3	8
118	Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 61, 104-108.	2.0	8
119	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	2.0	8
120	Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevacizumab: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 403-408.	1.0	8
121	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019, Volume 12, 2349-2358.	2.0	8
122	Efectos cutáneos adversos causados por erlotinib. <i>Actas Dermo-sifiligráficas</i> , 2008, 99, 54-60.	0.4	7
123	Professional burnout among Spanish medical oncologists. <i>Clinical and Translational Oncology</i> , 2009, 11, 86-90.	2.4	7
124	Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. <i>Clinical and Translational Oncology</i> , 2010, 12, 819-824.	2.4	7
125	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 553-558.	4.9	7
126	Can the Spanish care system assume the new costs of medications against cancer?. <i>Clinical and Translational Oncology</i> , 2008, 10, 96-101.	2.4	6

#	ARTICLE	IF	CITATIONS
127	Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. <i>Clinical and Translational Oncology</i> , 2014, 16, 914-920.	2.4	6
128	Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability. <i>Anticancer Research</i> , 2005, 25, 4611-4.	1.1	6
129	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.	2.6	5
130	How sustainable are new treatment strategies for NSCLC?. <i>Lancet Respiratory Medicine</i> , 2019, 7, 733-735.	10.7	5
131	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. <i>BMC Cancer</i> , 2021, 21, 977.	2.6	5
132	Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 1994, 30, 1043.	2.8	4
133	Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents. <i>Clinical and Translational Oncology</i> , 2007, 9, 161-171.	2.4	4
134	Pharmacogenetics in lung cancer for the lay doctor. <i>Targeted Oncology</i> , 2008, 3, 161-171.	3.6	4
135	Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). <i>Clinical and Translational Oncology</i> , 2011, 13, 328-334.	2.4	4
136	Oncology outside hospital: a new experience for the benefit of longer survivors. <i>Clinical and Translational Oncology</i> , 2011, 13, 249-253.	2.4	4
137	Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility. <i>Clinical and Translational Oncology</i> , 2014, 16, 107-112.	2.4	4
138	Patient Perspective on the Management of Cancer Pain in Spain. <i>Journal of Patient Experience</i> , 2020, 7, 1417-1424.	0.9	4
139	Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3216.	3.7	4
140	Dr. Neri et al.: Prognostic role of K-ras mutations in non-small cell lung cancer: Still an issue for open debate. <i>Lung Cancer</i> , 2006, 53, 397-398.	2.0	3
141	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	2.4	3
142	Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study). <i>Pain Management</i> , 2011, 1, 513-522.	1.5	3
143	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	2.8	3
144	Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 180-8.	2.8	3

#	ARTICLE	IF	CITATIONS
145	Study of the prevalence of tumour-related asthenia in Spanish cancer patients. <i>Clinical and Translational Oncology</i> , 2008, 10, 351-358.	2.4	2
146	Analysis of the elderly patient population in a tertiary-care university hospital. <i>European Journal of Cancer Care</i> , 2009, 18, 264-270.	1.5	2
147	Mujer de 68 años con síndrome de ojos bailarines. <i>Medicina Clínica</i> , 2019, 153, 475.	0.6	2
148	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. <i>BMC Urology</i> , 2015, 15, 15.	1.4	1
149	High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. <i>Clinical and Translational Oncology</i> , 2016, 18, 405-412.	2.4	1
150	Hipopigmentación capilar y cutánea secundaria a pazopanib. <i>Medicina Clínica</i> , 2021, 158, 246-246.	0.6	1
151	The Quality Oncology Practice Initiative program: Experience in Spain.. <i>Journal of Clinical Oncology</i> , 2017, 35, 214-214.	1.6	1
152	Cisplatin and vinorelbine combination chemotherapy in inoperable non small cell lung cancer (NSCLC) : a multicenter phase II trial. , 2000, 2, 84-90.		1
153	Re: "Treatment of Advanced Colorectal Cancer with Recombinant Interferon Alpha and Fluorouracil: Activity in Liver Metastasis" <i>Cancer Investigation</i> , 1994, 12, 101-102.	1.3	0
154	Corrigendum to "Second line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study" <i>Lung Cancer</i> , 2000, 29, 227.	2.0	0
155	Use of free circulating DNA for diagnosis, prognosis and treatment of cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 143-146.	1.6	0
156	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011, 13, 411-418.	2.4	0
157	Oncological translational research in the Spanish national health system: the INTRO study. <i>Clinical and Translational Oncology</i> , 2014, 16, 686-695.	2.4	0
158	European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish. <i>Clinical and Translational Oncology</i> , 2017, 19, 288-290.	2.4	0
159	Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 891-899.	0.6	0
160	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021, 17, e1162-e1169.	2.9	0
161	Isolation and characterization of lung cancer sphere-forming cells as platforms for the development of new therapeutic strategies.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22190-e22190.	1.6	0
162	Peritoneal Carcinomatosis and Multi-Organ Metastases are Prognostic Factors in Colorectal Cancer: A Retrospective Analysis. <i>Journal of Analytical Oncology</i> , 2016, 5, 5-13.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Differential expression of tumorspheres in CSC-markers and signaling pathways from non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23276-e23276.	1.6	0
164	EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23039-e23039.	1.6	0
165	Identification of quality care indicators in prostate cancer.. Journal of Clinical Oncology, 2017, 35, 213-213.	1.6	0
166	Oncology beyond the hospital: 7 years taking care of cancer patients from the very beginning until the last consequences.. Journal of Clinical Oncology, 2017, 35, 75-75.	1.6	0
167	Study on compliance with breakthrough cancer pain guidelines by medical oncologists in Spain.. Journal of Clinical Oncology, 2017, 35, e18260-e18260.	1.6	0
168	ECO Expertsâ€™ consensus on establishing renal cancer healthcare quality measures in Spain.. Journal of Clinical Oncology, 2020, 38, 220-220.	1.6	0
169	Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program.. Journal of Clinical Oncology, 2020, 38, 222-222.	1.6	0